Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb

 Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)


  • The collaboration will evaluate Nektar Therapeutics’ bempegaldesleukin in combination with BMS’ Opdivo (nivolumab) into multiple new registrational trials and the cost of trials will be shared upon the cost-sharing outlined in the terms of the original collaboration agreement
  • The companies have expanded their collaboration for bempeg + nivolumab from three ongoing registrational trials targeted for 1L metastatic melanoma, 1L cisplatin-ineligible metastatic urothelial cancer, 1L metastatic RCC to two additional trials for adjuvant melanoma & in muscle-invasive bladder cancer
  • Additionally, BMS to initiate and fund the P-I/II dose optimization and expansion study for bempeg + nivolumab in combination with axitinib to treat 1L RCC. Bempeg is a CD122-preferential IL-2 pathway agonist targeted for rapid activation and proliferation of cancer-killing immune cells

Click here to read full press release/ article | Ref: BMS | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on

Related post